Renal and Urinary Tract Cancer Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

Title: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Description: This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body.
 

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 y/o and older, who have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection
 

Status

Please contact site for study status

Contacts

Joni Beemsterboer, 415-600-3967

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Description: The purpose of this study is to determine the efficacy and safety of nivolumab versus placebo in participants who have undergone radical surgery for invasive urothelial cancer

Investigators

Eligibility Requirements

Subjects 18 y/o and older with invasive urothelial cancer at high risk of recurrence originating in the bladder, ureter, or renal pelvis; must have had radical surgical resection (e.g. radical cystectomy), performed within the last 90 days; must have disease free status as determined by imaging within 4 weeks of dosing

Status

Active and open to enrollment

Contacts

Madeline Decker, 415-600-3613

A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma

Description: This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 y/o and older

Status

Please contact site for study status

Contacts

Madeline Decker, 415-600-3613